HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: A prospective randomized trial

Human Reproduction

Volumn 16, Issue 2, 2001, Pages 319-325

  Ng, Ernest Hung Yu ^a,b   Lau, Estella Yee Lan ^a   Yeung, William Shu Biu ^a   Ho, Pak Chung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

HMG; ICSI; Oocyte and embryo quality; Ovarian stimulation; Recombinant human FSH

Indexed keywords

FOLLITROPIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; BLASTOMERE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; FERTILIZATION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; METAPHASE; MORPHOLOGY; NIDATION; OOCYTE DEVELOPMENT; OOCYTE MATURATION; OVULATION INDUCTION; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ZONA PELLUCIDA;

EID: 0035134858     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.2.319     Document Type: Article

References (44)

1. Oocyte quality in patients with severe ovarian hyperstimulation syndrome (OHSS)
2. Follicle-stimulating hormone or human menopausal gonadotrophin for ovarian stimulation in in vitro fertilization cycles: A meta-analysis
3. Does ovarian hyperstimulation syndrome affect the quality of oocytes?
4. Oocyte morphology does not affect fertilization rate, embryo quality and implantation rate after intracytoplasmic sperm injection
5. Reducing the time of spermatozoa-oocyte interaction in human IVF improves the implantation rate
6. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): Results of a randomized comparative study in women undergoing assisted reproductive techniques
7. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction
8. Follicle-stimulating hormone versus human menopausal gonadotrophin for in vitro fertilization cycles: A meta-analysis
9. Oocyte morphology does not correlate with fertilization rate and embryo quality after intracytoplasmic sperm injection
10. Noninvasive assessment of glucose and pyruvate uptake by human embryos after intracytoplasmic sperm injection and during the formation of pronuclei
11. Prognostic value of first polar body morphology on fertilization rate and embryo quality in intracytoplasmic sperm injection
12. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome
13. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone
14. Intracytoplasmic sperm injection does not overcome an oocyte defect in previous fertilization failure with conventional in-vitro fertilization and normal spermatozoa
15. Follicular hormonal environment and embryo quality in women with endometriosis
16. Sequential analysis of zona thickness during in vitro culture of human zygotes: Correlation with embryo quality, age, and implantation
17. Composition of commercial gonadotropin preparations extracted from human post-menopausal urine: Characterization of non-gonadotropin proteins
18. Type of stimulation protocol affects oocyte maturity, fertilization rate, and cleavage rate after intracytoplasmic sperm injection
19. Normal development and metabolic activity of preimplantation embryos in vitro from patients with polycystic ovaries
20. Influence of serum luteinising hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovary syndrome
21. Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin
22. Outcome from consecutive in-vitro fertilization/intracytoplasmic sperm injection attempts in the final group treated with urinary gonadotrophins and the first group treated with recombinant follicle stimulating hormone
23. Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients
24. Improved oocyte quality is obtained with follicle stimulating hormone alone than with follicle stimulating hormone/human menopausal gonadotrophin combination
25. High serum oestradiol levels in fresh IVF cycles do not impair implantation and pregnancy rates in subsequent FET cycles
26. A prospective, randomized, assessor-blind, multicentre study comparing recombinant follicle-stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization
27. Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies
28. Use of recombinant human follicle-stimulating hormone for in vitro fertilization-embryo transfer after severe systemic immunoglobulin E-mediated reaction to urofollitropin
29. Lack of correlation between oocyte-corona-cumulus complex morphology and nuclear maturity of oocytes collected in stimulated cycles for intracytoplasmic sperm injection
30. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization
31. Hypersecretion of luteinising hormone, infertility and miscarriage
32. Variability in the immunoreactive and bioactive follicle stimulating hormone content of human urinary menopausal gonadotrophin preparation
33. The relationship between follicular fluid aspirate volume and oocyte maturity in in-vitro fertilization cycles
34. Oocyte morphology predicts outcome of intracytoplasmic sperm injection
35. Intracytoplasmic sperm injection facilitates fertilization even in the most severe forms of male infertility: Pregnancy outcome correlates with maternal age and number of eggs available
36. Early cleavage of in-vitro fertilized human embryos to the 2-cell stage: A novel indicator of embryo quality and viability
37. Reduced in vitro fertilization of human oocytes from patients with raised basal luteinising hormone levels during the follicular phase
38. Recombinant human follicle stimulating hormone versus human menopausal gonadotrophin induction: Effects in mature follicle endocrinology
39. Oocyte assessment and biological performance
40. Intracytoplasmic sperm injection after follicle stimulation with highly purified human follicle-stimulating hormone compared with human menopausal gonadotrophin
41. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction
42. Effects of cigarette smoking and age on the maturation of human oocytes